Enzymatics Inc. has acquired ArcherDx Inc. in a deal valued at up to $50 million.
ArcherDx, headquartered in Denver, Colo., develops software used to analyze cancer treatments.
Complete access to real-time information and analysis of news and trends in the industry.
14-Day Free Trial
No credit card required. Complete access to articles, breaking news and industry data.
Have an account? Sign In